{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:29:18Z","timestamp":1790375358192,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jena Graduate Academy and the federal state of Thuringia"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>BCR::ABL1 inhibitors, the treatment of choice for the majority of patients with chronic myeloid leukaemia (CML), can cause vascular side effects that vary between agents. The exact underlying mechanisms are still poorly understood, but the vascular endothelium has been proposed as a site of origin. The present study investigates the effects of three BCR::ABL1 inhibitors, ponatinib, nilotinib and imatinib, on angiogenesis and signalling in human endothelial cells in response to vascular endothelial growth factor (VEGF). The experiments were performed in endothelial cells isolated from human umbilical veins. After exposure to imatinib, ponatinib and nilotinib, the angiogenic capacity of endothelial cells was assessed in spheroid assays. VEGF-induced signalling pathways were examined in Western blotting experiments using different specific antibodies. RNAi technology was used to downregulate proteins of interest. Intracellular cGMP levels were measured by ELISA. Imatinib had no effect on endothelial function. Ponatinib inhibited VEGF-induced sprouting, while nilotinib increased spontaneous and VEGF-stimulated angiogenesis. These effects did not involve wild-type ABL1 or ABL2, as siRNA-mediated knockdown of these kinases did not affect angiogenesis and VEGF signalling. Consistent with their effects on sprouting, ponatinib and nilotinib affected angiogenic pathways in opposite directions. While ponatinib inhibited VEGF-induced signalling and cGMP formation, nilotinib activated angiogenic signalling, in particular phosphorylation of extracellular signal-regulated kinase 1\/2 (Erk1\/2). The latter occurred in an epidermal growth factor receptor (EGFR)-dependent manner possibly via suppressing Fyn-related kinase (FRK), a negative regulator of EGFR signalling. Both, pharmacological inhibition of Erk1\/2 or EGFR suppressed nilotinib-induced angiogenic sprouting. These results support the notion that the vascular endothelium is a site of action of BCR::ABL1 inhibitors from which side effects may arise, and that the different vascular toxicity profiles of BCR::ABL1 inhibitors may be due to their different actions at the molecular level. In addition, the as yet unknown pro-angiogenic effect of nilotinib should be considered in the treatment of patients with comorbidities associated with pathological angiogenesis, such as ocular disease, arthritis or obesity.<\/jats:p>","DOI":"10.1007\/s11010-024-05070-5","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:02:37Z","timestamp":1721066557000},"page":"1627-1643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling"],"prefix":"10.1007","volume":"480","author":[{"given":"Darya","family":"Zibrova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"5070_CR1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","volume":"8","author":"PC Nowell","year":"1962","unstructured":"Nowell PC (1962) The minute chromosome (Phl) in chronic granulocytic leukemia. Blut 8:65\u201366","journal-title":"Blut"},{"issue":"6","key":"5070_CR2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7(6):441\u2013453","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"5070_CR3","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108(7):2332\u20132338","journal-title":"Blood"},{"issue":"1","key":"5070_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E et al (2008) Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53\u201355","journal-title":"Blood"},{"issue":"15","key":"5070_CR5","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE et al (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123(15):2875\u20132880","journal-title":"Cancer"},{"issue":"4","key":"5070_CR6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","volume":"32","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, Possick J, Fradley M (2018) Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Rev 32(4):289\u2013299","journal-title":"Blood Rev"},{"issue":"6","key":"5070_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-016-0514-0","volume":"18","author":"J Herrmann","year":"2016","unstructured":"Herrmann J (2016) Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system? Curr Oncol Rep 18(6):33","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"5070_CR8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/gtc.12022","volume":"18","author":"D Kitagawa","year":"2013","unstructured":"Kitagawa D et al (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 18(2):110\u2013122","journal-title":"Genes Cells"},{"issue":"12","key":"5070_CR9","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12):4055\u20134063","journal-title":"Blood"},{"issue":"9","key":"5070_CR10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M et al (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25(9):1035\u20131044","journal-title":"Nat Biotechnol"},{"issue":"3","key":"5070_CR11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23(3):329\u2013336","journal-title":"Nat Biotechnol"},{"issue":"12","key":"5070_CR12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085231","volume":"8","author":"EM Chislock","year":"2013","unstructured":"Chislock EM, Pendergast AM (2013) Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS ONE 8(12):e85231","journal-title":"PLoS ONE"},{"issue":"30","key":"5070_CR13","doi-asserted-by":"crossref","first-page":"12432","DOI":"10.1073\/pnas.1304188110","volume":"110","author":"EM Chislock","year":"2013","unstructured":"Chislock EM, Ring C, Pendergast AM (2013) Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A 110(30):12432\u201312437","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"5070_CR14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","volume":"58","author":"A Gover-Proaktor","year":"2017","unstructured":"Gover-Proaktor A et al (2017) Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma 58(6):1455\u20131467","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5070_CR15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","volume":"60","author":"A Gover-Proaktor","year":"2019","unstructured":"Gover-Proaktor A et al (2019) Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma 60(1):189\u2013199","journal-title":"Leuk Lymphoma"},{"key":"5070_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294438","author":"Y Wang","year":"2023","unstructured":"Wang Y, Travers RJ, Farrell A, Lu Q, Bays JL, Stepanian A, Chen C, Jaffe IZ (2023) Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0294438","journal-title":"PLoS ONE"},{"issue":"11","key":"5070_CR17","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic E et al (2017) Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia 31(11):2388\u20132397","journal-title":"Leukemia"},{"issue":"1","key":"5070_CR18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1074\/jbc.M004392200","volume":"276","author":"R Heller","year":"2001","unstructured":"Heller R et al (2001) L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276(1):40\u201347","journal-title":"J Biol Chem"},{"issue":"6","key":"5070_CR19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1042\/BCJ20160980","volume":"474","author":"D Zibrova","year":"2017","unstructured":"Zibrova D et al (2017) GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. Biochem J 474(6):983\u20131001","journal-title":"Biochem J"},{"key":"5070_CR20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/978-1-4939-7598-3_33","volume":"1732","author":"K Spengler","year":"2018","unstructured":"Spengler K, Gro\u00dfe S, Kryeziu N, Knierim A, Heller R (2018) Studying the role of AMPK in angiogenesis. Methods Mol Biol 1732:519\u2013537","journal-title":"Methods Mol Biol"},{"issue":"46","key":"5070_CR21","doi-asserted-by":"crossref","first-page":"27489","DOI":"10.1074\/jbc.270.46.27489","volume":"270","author":"DR Alessi","year":"1995","unstructured":"Alessi DR et al (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270(46):27489\u201327494","journal-title":"J Biol Chem"},{"issue":"20","key":"5070_CR22","doi-asserted-by":"crossref","first-page":"19472","DOI":"10.1074\/jbc.M414221200","volume":"280","author":"Y Kuma","year":"2005","unstructured":"Kuma Y, Sabio G, Bain J, Shpiro N, M\u00e1rquez R, Cuenda A (2005) BIRB796 Inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 280(20):19472\u201319479","journal-title":"J Biol Chem"},{"issue":"3","key":"5070_CR23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/onc.2012.589","volume":"33","author":"L Jin","year":"2014","unstructured":"Jin L, Craven RJ (2014) The Rak\/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor. Oncogene 33(3):326\u2013335","journal-title":"Oncogene"},{"issue":"Pt 1","key":"5070_CR24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/BJ20040285","volume":"382","author":"M Welsh","year":"2004","unstructured":"Welsh M et al (2004) The tyrosine kinase FRK\/RAK participates in cytokine-induced islet cell cytotoxicity. Biochem J 382(Pt 1):261\u2013268","journal-title":"Biochem J"},{"issue":"6","key":"5070_CR25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.23442","volume":"88","author":"EA Coon","year":"2013","unstructured":"Coon EA et al (2013) Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol 88(6):534\u2013535","journal-title":"Am J Hematol"},{"issue":"19","key":"5070_CR26","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369(19):1783\u20131796","journal-title":"N Engl J Med"},{"issue":"8","key":"5070_CR27","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3109\/10428194.2014.994205","volume":"56","author":"J Gora-Tybor","year":"2015","unstructured":"Gora-Tybor J et al (2015) Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma 56(8):2309\u20132314","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"5070_CR28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27(6):1316\u20131321","journal-title":"Leukemia"},{"issue":"9","key":"5070_CR29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","volume":"50","author":"P Di Gion","year":"2011","unstructured":"Di Gion P et al (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50(9):551\u2013603","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"5070_CR30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"5070_CR31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","volume":"87","author":"C Tanaka","year":"2010","unstructured":"Tanaka C et al (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87(2):197\u2013203","journal-title":"Clin Pharmacol Ther"},{"issue":"62","key":"5070_CR32","doi-asserted-by":"crossref","first-page":"31958","DOI":"10.18632\/oncotarget.24110","volume":"9","author":"N Ai","year":"2018","unstructured":"Ai N et al (2018) Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway. Oncotarget 9(62):31958\u201331970","journal-title":"Oncotarget"},{"issue":"20","key":"5070_CR33","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1093\/emboj\/cdg512","volume":"22","author":"EA Burton","year":"2003","unstructured":"Burton EA, Plattner R, Pendergast AM (2003) Abl tyrosine kinases are required for infection by Shigella flexneri. EMBO J 22(20):5471\u20135479","journal-title":"EMBO J"},{"key":"5070_CR34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1146\/annurev-pharmtox-070115-095427","volume":"56","author":"SJ Forrester","year":"2016","unstructured":"Forrester SJ et al (2016) Epidermal growth factor receptor transactivation: mechanisms, pathophysiology, and potential therapies in the cardiovascular system. Annu Rev Pharmacol Toxicol 56:627\u2013653","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"5070_CR35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK et al (2006) VEGF receptor signalling\u2014in control of vascular function. Nat Rev Mol Cell Biol 7(5):359\u2013371","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"5070_CR36","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1172\/JCI119868","volume":"100","author":"A Papapetropoulos","year":"1997","unstructured":"Papapetropoulos A et al (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100(12):3131\u20133139","journal-title":"J Clin Invest"},{"issue":"14","key":"5070_CR37","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1074\/jbc.M110.108688","volume":"285","author":"N Stahmann","year":"2010","unstructured":"Stahmann N et al (2010) Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. J Biol Chem 285(14):10638\u201310652","journal-title":"J Biol Chem"},{"key":"5070_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-018-0150-5","author":"O Contreras","year":"2018","unstructured":"Contreras O, Villarreal M, Brandan E (2018) Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation. Skelet Muscle. https:\/\/doi.org\/10.1186\/s13395-018-0150-5","journal-title":"Skelet Muscle"},{"issue":"4","key":"5070_CR39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cyto.b.21091","volume":"86","author":"U Schnetzke","year":"2014","unstructured":"Schnetzke U, Fischer M, Frietsch JJ, Finkensieper A, Clement JH, Hochhaus A, La Ros\u00e9e P (2014) Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses track. Cytometry B Clin Cytom 86(4):229\u2013235","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"5070_CR40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-016-9623-3","volume":"35","author":"RK Goel","year":"2016","unstructured":"Goel RK, Lukong KE (2016) Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology. Cancer Metastasis Rev 35(2):179\u2013199","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"5070_CR41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-014-1461-y","volume":"119","author":"L Hua","year":"2014","unstructured":"Hua L et al (2014) FRK suppresses the proliferation of human glioma cells by inhibiting cyclin D1 nuclear accumulation. J Neurooncol 119(1):49\u201358","journal-title":"J Neurooncol"},{"issue":"1","key":"5070_CR42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12031-014-0355-y","volume":"55","author":"Q Shi","year":"2015","unstructured":"Shi Q et al (2015) FRK inhibits migration and invasion of human glioma cells by promoting N-cadherin\/beta-catenin complex formation. J Mol Neurosci 55(1):32\u201341","journal-title":"J Mol Neurosci"},{"issue":"4","key":"5070_CR43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2009.02.012","volume":"15","author":"EK Yim","year":"2009","unstructured":"Yim EK et al (2009) Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304\u2013314","journal-title":"Cancer Cell"},{"issue":"1","key":"5070_CR44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-012-0933-1","volume":"110","author":"X Zhou","year":"2012","unstructured":"Zhou X et al (2012) FRK controls migration and invasion of human glioma cells by regulating JNK\/c-Jun signaling. J Neurooncol 110(1):9\u201319","journal-title":"J Neurooncol"},{"key":"5070_CR45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","volume":"2","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Herrmann J (2018) Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol 2:13","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"5070_CR46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","volume":"26","author":"AC Dudley","year":"2023","unstructured":"Dudley AC, Griffioen AW (2023) Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis 26(3):313\u2013347","journal-title":"Angiogenesis"},{"issue":"2","key":"5070_CR47","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.survophthal.2021.07.001","volume":"67","author":"MA Yassin","year":"2022","unstructured":"Yassin MA, Ata F, Mohamed SF, Alkhateeb A, Naeem U, Al-Qatami AI, Nashwan AJ, Fernyhough LJ (2022) Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: a review. Surv Ophthalmol 67(2):530\u2013543","journal-title":"Surv Ophthalmol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-05070-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:19:01Z","timestamp":1740057541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-05070-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["5070"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-05070-5","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DZ, TE and RH declare no competing interests. AH received research support from Bristol Myers Squibb, Incyte, Novartis and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research presented here conforms to all relevant ethical regulations. Umbilical cords, used for isolation of human endothelial cells, were obtained anonymously in accordance with the Declaration of Helsinki \u201cEthical principles for Medical Research Involving Human Subjects\u201d (1964). The donors were informed and gave their written consent. The study was approved by ethics committee of the Jena University Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}